Chariots of Fire and CRISPR: Why Genomic Doping Is the Olympics' Next Impossible Problem

What is gene doping and why are sports authorities losing sleep over it? Gene doping is the non-therapeutic use of genes, genetic elements, or cells to enhance athletic performance. Unlike chemical doping, which leaves detectable traces, genetic modifications can be nearly impossible to distinguish from natural biology - making it one of the most difficult enforcement challenges in the history of competitive sport.

In the six months before the 2026 Winter Olympics in Milan-Cortina, more than 7,100 anti-doping tests were conducted on 2,900 athletes by the International Testing Agency. The scale was unprecedented. The methods were largely unchanged.

Blood and urine. Chemical markers. Traditional detection.

The World Anti-Doping Agency has banned gene doping since 2003, defining it as the non-therapeutic use of genes, genetic elements, or cells that have the capacity to enhance athletic performance. The 2026 WADA Prohibited List classifies gene and cell doping under Method M3 - explicitly covering gene editing, gene silencing, gene transfer technologies, and the use of normal or genetically modified cells.

What WADA cannot yet do, reliably, is detect it.

The Enforcement Gap

The fundamental problem with gene doping is that it works differently from chemical doping. A synthetic hormone shows up as a foreign substance in a blood sample. A gene edit does not. If a CRISPR modification causes an athlete's muscle cells to produce more of their own naturally occurring proteins - EPO for red blood cell production, IGF-1 for muscle growth, or a reduction in myostatin, the protein that limits muscle mass - those substances are biologically indistinguishable from what the body produces naturally.

Detecting the difference requires either finding the delivery mechanism (a viral vector used to introduce the gene) or comparing an athlete's current genome against a stored baseline. Both approaches face significant practical obstacles. Vector detection requires knowing what to look for. Genome comparison raises immediate questions about genetic privacy.

WADA approved its first gene doping test protocol in 2021 - a real-time PCR test capable of detecting the human erythropoietin gene in whole blood. It was a meaningful step. It covers one gene, delivered one way.

The broader landscape of potential targets is far wider. Researchers have identified approximately 200 genes associated with athletic fitness and performance. EPO for endurance. Myostatin for muscle mass. IGF-1 for growth. VEGF for vascularization. PPAR-delta - which in animal studies increased exercise tolerance by 60 to 70 percent with no change in training volume.

In 2023, researchers at the University of Cologne purchased vials on the black market advertised as containing EPO-gene and IGF-1-gene plasmid preparations. Analysis confirmed the presence of transgenic EPO-DNA - meaning commercially available gene doping preparations already exist, even if current efficacy is limited.

The Athletic Frontier

Gene doping faces real biological constraints. Athletic performance at elite level is polygenic - it depends on hundreds of genes in combination. No single edit transforms an average athlete into a champion. But among athletes who are already genetically predisposed and highly trained, even a small genomic advantage can be the difference between a podium finish and elimination.

Mauro Mandrioli, associate professor of genetics at the University of Modena, has proposed adding a genomic component to the athlete biological passport - a longitudinal system that tracks biological parameters over time. A genomic passport would establish a baseline sequence for each athlete, against which future samples could be compared. Technically feasible. Expensive. Logistically complex. And it would raise serious questions about what sports authorities are entitled to know about an athlete's DNA.

The conversation about gene doping ultimately forces a question sport has never had to confront at this scale: what is a natural genetic advantage, and what is an engineered one?

Eero Mantyranta, the Finnish cross-country skier who won two gold medals at the 1964 Winter Olympics, had a naturally occurring mutation that caused his body to produce excess EPO - a red blood cell advantage that would trigger a positive chemical test today. He was never sanctioned. The mutation was his birthright.

If CRISPR can now confer that same birthright, the line between natural and engineered becomes commercially exploitable.

The chariots are faster than ever. The rules are still being written.